CLS-TA meets primary, secondary endpoints in phase 2 clinical trial
CLS-TA has met its primary endpoint of achieving a statistically significant mean change in central subfield thickness from baseline in the phase 2 Dogwood trial, according to topline data released by Clearside Biomedical.
The Dogwood trial evaluated the safety and efficacy of CLS-TA (triamcinolone acetonide) in 22 patients with macular edema associated with noninfectious uveitis. A single treatment of CLS-TA resulted in a statistically significant mean change in central subfield thickness from baseline to 8 weeks. The secondary endpoint of statistical significance in mean increase from baseline in best corrected visual acuity was also achieved, a press release said.
“The data from this clinical trial continue to provide support for the approach to treatment of certain blinding eye diseases through [suprachoroidal space] administration and the potential for an effective and safe option for the treatment of uveitis using CLS-TA,” Daniel H. White, CEO and president of Clearside, said in the release.
The company plans to submit a full data set for presentation at an upcoming meeting.